In this webinar, Dr. Ioannis Loisios-Konstantinidis from Novartis, Switzerland discussed:
- Opportunities and challenges in conducting virtual bioequivalence
- IVIVE-PBPK in biopharmaceutics
- An quantitative risk assessment approach for virtual bioequivalence
- Role of inter-occasion variability and pharmacokinetic properties in virtual bioequivalence
